BioCentury | Oct 3, 2019
Financial News

OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic. The company plans to submit in six...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BioCentury | May 18, 2018

China comes to Europe

The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...
BioCentury | Sep 12, 2016

Adding to A1c

Diabetes patients and researchers are zeroing in on a collection of endpoints they say would be more useful than HbA1c for choosing among treatment options. The standard endpoint is useful in predicting serious microvascular complications...
BioCentury | Jan 4, 2016

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BioCentury | Dec 21, 2015
Financial News

Kahr Medical completes venture financing

Kahr Medical Ltd. , Jerusalem, Israel Business: Autoimmune, Cancer Date completed: 2015-12-15 Type: Venture financing Raised: $12 million Investors: Korea Investment Partners; Mirae Asset Venture Investment; DSC Investment; Flerie Invest AB Note: Kahr Medical raised $12...
BioCentury | Nov 16, 2015
Clinical News

Aclerastide: Phase III discontinued

Derma said it will discontinue its 2 double-blind Phase III trials evaluating once-daily 0.03% DSC127 in patients with chronic, non-healing diabetic foot ulcers based on a pre-specified interim futility analysis of the primary endpoint of...
BioCentury | Nov 13, 2015
Top Story

Derma misses 'one shot' at drug development

Derma Sciences Inc. (NASDAQ:DSCI) fell $1.56 (28%) to $4.04 on Thursday on news it will terminate development of aclerastide ( DSC127 ), the only candidate in the company's drug development portfolio. Derma said that after an...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Filamin A (FLNA); regulator of calcineurin 1 (RCAN1; DSC1)

...periventricular heterotopia (PH) caused by a deficiency in RCAN1 . In rats, shRNA knockdown of RCAN1...
...PH pathology - compared with scrambled shRNA. In the RCAN1-knockdown rats, overexpression of FLNA prevented RCAN1-induced... selectively increase FLNA signaling in brain tissues. TARGET/MARKER/PATHWAY: Filamin A (FLNA) ; regulator of calcineurin 1 (RCAN1; DSC1...
BioCentury | Jan 27, 2014

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €2.95 (21%) to €11.36 on Friday after EMA's CHMP recommended against approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination...
Items per page:
1 - 10 of 38